ISN-WCN 2019 Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.
This lecture by prof. David Cherney was part of a CME accredited symposium "SGLT2 inhibition in CKD: Discussing the key questions and evidence"
Prof. David Cherney - Associate Professor, Department of Medicine, University of Toronto, ON, Canada
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- SGLT2 inhibition in CKD: Discussing the key questions & evidenceThe known and unknown of SGLT2 inhibition in CKD
Carol Pollock, MD
- SGLT2 inhibition in CKD: Discussing the key questions & evidenceOutcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?
Mark Cooper, MD